Summary:
A Phase 3, randomized, double-blind, placebocontrolled study to assess the efficacy and safety of rifaximin for the delay of the first episode of overt hepatic encephalopathy (OHE) decompensation in advanced liver cirrhosis, defined by the presence of medically controlled ascites.
Qualified Participants Must:
• Between age 18 and 70
•
2. Diagnosed with Liver Cirrhosis
•
3. Controlled ascites
Qualified Participants May Receive:
$65.00 per visit
Total comp. = over $1000.00